product name Carboplatin
Description: Carboplatin (also known as JM-8, CBDCA, NSC 241240) is a DNA synthesis inhibitor by binding to DNA and interfering with the cells repair mechanism in cancer cells. It is activated intracellularly to form reactive platinum complexes that bind to nucleophilic groups such as GC-rich sites in DNA, thereby inducing intrastrand and interstrand DNA cross-links, as well as DNA-protein cross-links. These carboplatin-induced DNA and protein effects result in apoptosis and cell growth inhibition.
References: Cancer Chemother Pharmacol. 2008 Oct;62(5):769-78; Mol Cancer Ther. 2012 Sep;11(9):1948-58.
371.25
Formula
C6H12N2O4Pt
CAS No.
41575-94-4
Storage
-20℃ for 3 years in powder form
-80℃ for 2 years in solvent
Solubility (In vitro)
DMSO: <1 mg/mL
Water: 14 mg/mL (37.7 mM)
Ethanol: <1 mg/mL
Solubility (In vivo)
Water: 14 mg/mL
Synonyms
JM-8, CBDCA, NSC 241240
other peoduct :References PubMed ID：:http://www.ncbi.nlm.nih.gov/pubmed/19411444
| In Vitro |
In vitro activity: Carboplatin exhibits an inhibitory effect on cell proliferation in a human ovarian cancer cell line panel, including A2780, SKOV3, and IGROV-1 cells with IC50 of 6.1 μM, 12.4 μM and 2.2 μM, respectively. Carboplatin also show the anti-proliferative activities in lung carcinoid cell line, such as UMC-11, H727, and H835 cells with IC50 of 36.4 μM, 3.4 μM and 35.8 μM, respectively. Kinase Assay: Cell Assay: 3-(4,5-dimethylthiazol-2yl)-2,5-diphenyltetrazolium bromide (MTT) assays: Exponentially growing A2780, SKOV3, IGROV-1 and HX62 ovarian cancer cells are plated in 96 well plates. A range of drug concentrations are added and the plates are incubated for 72 hours to allow for 3–4 doubling times. Each experiment is carried out in triplicate. Sulforhodamine B (SRB) assays: Exponentially growing A2780 cells are plated in 96 well microtitre plates. For experiments studying concomitant exposure, cells are exposed to increasing concentrations of both drugs for 96 hours. For experiments studying the effect of sequence of exposure to 17-AAG or carboplatin cells are exposed to increasing concentrations of 17-AAG or carboplatin for 24 hours. A period of 24-hour exposure to the first agent is chosen so that the A2780 cells would be exposed to the first drug for at least one doubling time (18-24 hours). The cells are then washed with sterile phosphate buffered saline and the medium is replenished. Following this, the second drug (to which the cells are not exposed to in the first 24 hours) or medium is added for 96 hours. All experiments are carried out in triplicate. The results of combination studies are analyzed using the well-established principles of median effect analysis method. The effects of the combination are calculated using an in-house spreadsheet. |
|---|---|
| In Vivo | In A2780 tumor xenografts, Carboplatin (60 mg/kg via i.p.) given as single agents shows a modest antitumor effect with the relative tumor volumes on day 6 of 8.4 compared to the control of 11.9, and the day 6 tumor weights relative to control (T/C) of 67%. For the VC8 (Brca2-deficient) xenografts, Carboplatin treatment delays tumor growth and reduces tumor mass by 42% compared to the vehicle group. |
| Animal model | Fmale athymic NCr nude mice (nu/nu) with A2780 human ovarian cancer xenograft |
| Formulation & Dosage | Dissolved in 43% ethanol, 33% polypropylene glycol and 24% cremaphor diluted 1:7 with sterile water; 60 mg/kg; i.p. injection |
| References | Cancer Chemother Pharmacol. 2008 Oct;62(5):769-78; Mol Cancer Ther. 2012 Sep;11(9):1948-58. |
